SITE012-0110

SITE012 (BRA) › SITE012-0110

SITE012-0110

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2026-01-05

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 60); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.